Sarissa Capital Sells 25.7M Amarin Shares, Cutting Stake to 6.09%
AMRN is trading near its 52-week low of $12.96 (8.6% above the low).
Summary
Activist investor Sarissa Capital sold 25.7 million Amarin shares, reducing its stake to 6.09% following the Supreme Court loss and steep revenue decline.
Key Events · Ownership and Investor Activity · AMRN
-
Sarissa Sells 25.7M Shares
Sarissa Capital Management and Alexander Denner sold 25,743,900 ordinary shares on August 24-25, 2026, at prices between $14.00 and $14.08 per ADS.
-
Stake Reduced to 6.09%
The sales reduced Sarissa's beneficial ownership to 25,743,900 ordinary shares, representing 6.09% of the 422,456,685 shares outstanding as of July 24, 2026.
-
Post-Supreme Court Exit
The sale follows the June 4, 2026 Supreme Court ruling against Amarin in its 'skinny label' case against Hikma, a major legal setback for the VASCEPA franchise.
-
Revenue Decline Context
Amarin reported Q2 2026 revenue fell 42% to $42.2 million, with product sales down 16% and licensing income nearly vanishing.
Analysis · AMRN · Life Sciences
Sarissa Capital Management, led by Alexander Denner, sold 25.7 million ordinary shares of Amarin over two days at prices between $14.00 and $14.08 per ADS. This is a significant reduction in the activist investor's position, dropping its ownership to 6.09% of outstanding shares. The sale comes just two months after the U.S. Supreme Court ruled against Amarin in its 'skinny label' case against Hikma, a major legal setback that has pressured the company's VASCEPA franchise. The timing suggests Sarissa is reducing exposure following the adverse ruling and the company's 42% revenue decline reported in Q2 2026.
How filings like this one have moved
In the 30 days to Aug 27, 2026, 36.8% of the 3372 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMRN was trading at $14.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $301.9M. The 52-week trading range was $12.96 to $20.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.